en
svPress releases
Regulatory press release 2021-10-13
Xspray Pharma has obtained results from bioequivalence studies with HyNap-Dasa ANDA and decides to focus on its improved dasatinib product, Dasynoc™
Press release 2021-08-30
All participants in Xspray Pharma studies have received their dose of generic version of dasatinib, HyNap-Dasa ANDA
Press release 2021-08-06
Xspray Pharma has initiated studies with generic version of dasatinib, HyNap-Dasa ANDA
Regulatory press release 2021-08-06
Xspray Pharma publishes interim report Q2 , January – June 2021
Regulatory press release 2021-07-28
Xspray Pharma announces achievement of bioequivalence compared with reference product from bioequivalence study with HyNap-Dasa 505(b)(2)
Press release 2021-06-28
All participants in Xspray Pharma’s study have received their dose of the improved version of dasatinib
Press release 2021-06-23
Xspray Pharma’s two incentive programs are fully subscribed
Press release 2021-06-10
Xspray Pharma commences study with improved version of dasatinib
Regulatory press release 2021-05-20
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2021-05-06